Literature DB >> 28189431

The Sendai and Fukuoka consensus criteria for the management of branch duct IPMN - A meta-analysis on their accuracy.

Max Heckler1, Christoph W Michalski1, Susanne Schaefle1, Jörg Kaiser1, Markus W Büchler1, Thilo Hackert2.   

Abstract

INTRODUCTION: The risk of malignancy in branch duct intraductal papillary mucinous neoplasia of the pancreas (BD-IPMN) is controversially debated. An increasing number of studies report on outcomes using the Sendai or Fukuoka consensus criteria for treatment decision-making. The objective of this work was to evaluate the diagnostic accuracy of the Sendai and Fukuoka criteria.
METHODS: We systematically reviewed studies on Sendai or Fukuoka criteria-guided management of BD-IPMN. Pooled sensitivity, specificity and diagnostic odds ratios as compound measures of diagnostic accuracy were calculated from studies matching the inclusion criteria. The meta-analysis was performed using a random effects model.
RESULTS: Fifteen studies with a total of 2710 patients were included. Twelve of these used the Sendai criteria. In these studies, 23% of Sendai-negative patients had a high grade dysplastic lesion or an invasive carcinoma in final histology. Pooled sensitivity was 56%, specificity was 74% and the diagnostic odds ratio for malignancy in Sendai-positive lesions was 7.45. When the results of follow-up examinations were included, diagnostic accuracy improved significantly (14.66, p < 0.001). Three studies were identified that used the Fukuoka criteria for decision making. Of 200 patients with Fukuoka-negative lesions who underwent surgery, 22 had a malignant lesion in final histology (11%). Pooled sensitivity was 83%, specificity was 53% and the diagnostic odds ratio was 8.76.
CONCLUSION: The Fukuoka criteria have considerably improved sensitivity but still lack adequate specificity. For further reduction of a potential surgical overtreatment of BD-IPMN, the development of criteria with an increased specificity is required.
Copyright © 2017 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Guidelines; IPMN; Malignancy; Side branch

Mesh:

Year:  2017        PMID: 28189431     DOI: 10.1016/j.pan.2017.01.011

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  17 in total

1.  Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Mohammad A Al Efishat; Marc A Attiyeh; Anne A Eaton; Mithat Gönen; Denise Prosser; Anna E Lokshin; Carlos Fernández-Del Castillo; Keith D Lillemoe; Cristina R Ferrone; Ilaria Pergolini; Mari Mino-Kenudson; Neda Rezaee; Marco Dal Molin; Matthew J Weiss; John L Cameron; Ralph H Hruban; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Christopher L Wolfgang; Peter J Allen
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

Review 2.  Managing Incidental Pancreatic Cysts.

Authors:  Jennifer Phan; V Raman Muthusamy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

3.  Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms.

Authors:  Alan R Penheiter; Dinesh K Deelchand; Emily Kittelson; Sibel Erdogan Damgard; Stephen J Murphy; Daniel R O'Brien; William R Bamlet; Marie R Passow; Thomas C Smyrk; Fergus J Couch; George Vasmatzis; John D Port; Małgorzata Marjańska; Stephanie K Carlson
Journal:  Pancreatology       Date:  2017-11-14       Impact factor: 3.996

4.  Multimodal radiomics and cyst fluid inflammatory markers model to predict preoperative risk in intraductal papillary mucinous neoplasms.

Authors:  Kate A Harrington; Travis L Williams; Sharon A Lawrence; Jayasree Chakraborty; Mohammad A Al Efishat; Marc A Attiyeh; Gokce Askan; Yuting Chou; Alessandra Pulvirenti; Caitlin A McIntyre; Mithat Gonen; Olca Basturk; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; William R Jarnagin; Jeffrey A Drebin; Richard K Do; Peter J Allen; Amber L Simpson
Journal:  J Med Imaging (Bellingham)       Date:  2020-06-25

Review 5.  Application of Artificial Intelligence in the Management of Pancreatic Cystic Lesions.

Authors:  Shiva Rangwani; Devarshi R Ardeshna; Brandon Rodgers; Jared Melnychuk; Ronald Turner; Stacey Culp; Wei-Lun Chao; Somashekar G Krishna
Journal:  Biomimetics (Basel)       Date:  2022-06-14

Review 6.  Surgery of Cystic Tumors of the Pancreas - Why, When, and How?

Authors:  Jan G D'Haese; Jens Werner
Journal:  Visc Med       Date:  2018-06-14

7.  Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression.

Authors:  Vincent Bernard; Alexander Semaan; Jonathan Huang; F Anthony San Lucas; Feven C Mulu; Bret M Stephens; Paola A Guerrero; Yanqing Huang; Jun Zhao; Nabiollah Kamyabi; Subrata Sen; Paul A Scheet; Cullen M Taniguchi; Michael P Kim; Ching-Wei Tzeng; Matthew H Katz; Aatur D Singhi; Anirban Maitra; Hector A Alvarez
Journal:  Clin Cancer Res       Date:  2018-11-01       Impact factor: 12.531

Review 8.  Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).

Authors:  Joseph Carmicheal; Asish Patel; Vipin Dalal; Pranita Atri; Amaninder S Dhaliwal; Uwe A Wittel; Mokenge P Malafa; Geoffrey Talmon; Benjamin J Swanson; Shailender Singh; Maneesh Jain; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-30       Impact factor: 10.680

Review 9.  Radiomics in stratification of pancreatic cystic lesions: Machine learning in action.

Authors:  Vipin Dalal; Joseph Carmicheal; Amaninder Dhaliwal; Maneesh Jain; Sukhwinder Kaur; Surinder K Batra
Journal:  Cancer Lett       Date:  2019-10-17       Impact factor: 8.679

Review 10.  Predictive performance of factors associated with malignancy in intraductal papillary mucinous neoplasia of the pancreas.

Authors:  M Heckler; L Brieger; U Heger; T Pausch; C Tjaden; J Kaiser; M Tanaka; T Hackert; C W Michalski
Journal:  BJS Open       Date:  2018-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.